CBD Lights (Suzy Q x Northern Lights 5) EMT (AC/DC x Canna-Tsu): A Comprehensive Strain Guide

Introduction and Naming

CBD Lights (Suzy Q x Northern Lights 5) EMT (AC/DC x Canna-Tsu) is a deliberate convergence of two CBD-forward lineages. It marries the resin-heavy vigor of a Suzy Q x Northern Lights #5 cross (“CBD Lights”) with the low-THC, therapeutic clarity of an AC/DC x Canna-Tsu cross (“EMT”).

In practical terms, many breeders and growers shorthand this polyhybrid as (Suzy Q x NL5) x (AC/DC x Canna-Tsu). That formula signals a target chemotype centered on high CBD content, calm yet functional effects, and improved agronomic stability from the NL5 backbone.

The naming reflects both ancestry and intention. “CBD Lights” nods to Northern Lights’ reliable structure while emphasizing cannabidiol, and “EMT” evokes a wellness-first profile sourced from two proven CBD cultivars. Together, the name transparently telegraphs purpose: dependable structure with medically relevant cannabinoid ratios.

Historical Context and Breeding Motivation

High-CBD cannabis breeding accelerated in the early-to-mid 2010s as patient demand for non-intoxicating relief surged. Landmark clinical approvals such as Epidiolex for certain pediatric epilepsies validated CBD’s therapeutic potential, fueling the search for cultivars with stable CBD:THC ratios. By 2018, legal CBD sales in the U.S. topped billions annually, and consumer interest in CBD-dominant flower rose accordingly.

Northern Lights #5 has long been leveraged as a structural and yield stabilizer in breeding programs, with documented flower density and consistency across environments. Pairing NL5 with a CBD-dominant like Suzy Q offers a pathway to robust plants that still deliver elevated CBD percentages. The EMT side adds genetics from AC/DC and Canna-Tsu, both known for reliably low THC and calming terpene ensembles.

The motivation behind this composite cross is twofold: improve cultivation reliability while preserving or enhancing CBD’s therapeutic ratio. Many CBD lines can be finicky, with low yields or susceptibility to mildew. Introducing NL5 structure seeks to lift grams per square meter and bud integrity without letting THC overshadow CBD.

Genetic Lineage and Breeding Strategy

CBD Lights refers to Suzy Q x Northern Lights #5, which combines a CBD-rich backbone with NL5’s compact, resinous frame. Suzy Q has been reported in multiple lab results to reach double-digit CBD—often 10–20%—with minimal THC, while NL5 historically expresses 18–22% THC and negligible CBD. The breeder’s challenge in CBD Lights is to retain Suzy Q’s CBD skew while borrowing NL5’s agronomic strengths.

EMT refers to AC/DC x Canna-Tsu, a cross designed to consolidate low-THC CBD chemotypes. AC/DC commonly tests in the range of ~13–20% CBD with <1% THC, while Canna-Tsu (Cannatonic x Sour Tsunami) tends to produce CBD in the 7–15% range with correspondingly low THC. This side of the pedigree is CBD-forward and favored for daytime-friendly calm.

Combined as (Suzy Q x NL5) x (AC/DC x Canna-Tsu), the cross aims for a CBD-dominant distribution with structural resilience. Practically, breeders will pop large seed lots—often 50–200 seeds—to statistically capture multiple CBD-dominant phenotypes given NL5’s THC influence. Selections are often validated with HPLC tests at weeks 6–8 of flower, then re-tested post-cure to confirm CBD:THC ratios before cloning mothers.

In stable seed lines from this cross, expect a phenotypic split where 50–70% of plants lean CBD-dominant (>8:1 CBD:THC), 20–35% fall into balanced 1:1 to 4:1 territory, and a minority express THC-dominant traits. The exact distribution varies by filial generation, backcrossing, and the breeder’s prior selections. Over two to three filial generations, breeders can boost CBD-dominant recovery rates by >20 percentage points via targeted selection.

Appearance and Morphology

Visually, this cultivar tends to show medium-height plants with strong lateral branching, inheriting NL5’s node spacing and Suzy Q’s open-air flower formation. Internodes are moderately tight, averaging 3–6 cm in controlled indoor environments under 800–1000 PPFD. The structure readily accepts topping and low-stress training to form an even canopy.

Bud morphology is compact but not rock-hard, balancing airflow with market-friendly density. Calyx-to-leaf ratios are favorable, often reducing trim time by 10–20% compared to leafier CBD lines. Sugar leaves are narrow-to-medium, with a manageable resin film that cures to a frosty sheen.

As the plants mature, expect a color palette of lime to forest green, sometimes accented by lavender hues in cooler nights below 18°C. Pistils begin a bright tangerine and fade to copper as trichomes turn cloudy. Mature colas show uniform stacking, with even spear-topped flowers on trained mains.

Trichome coverage is notable for a CBD-dominant cultivar, a trait likely reinforced by NL5 ancestry. While resin heads average 70–90 microns, a modest percentage of 90–120 micron heads are common, which can aid in ice water extraction yields. Growers report 2–4% fresh-frozen rosin yields from top flowers under optimal handling, competitive for a CBD-leaning variety.

Aroma and Flavor

The nose opens with a clean herbal core anchored by myrcene and pinene, evoking crushed pine needles, fresh basil, and a hint of sweet hay. Secondary tones—likely from beta-caryophyllene and humulene—add peppery spice and a subtle woody depth. In many phenotypes, a citrus lift from limonene surfaces after grind.

On the exhale, expect a crisp, pine-led finish with a soft pepper echo and mineral dryness. Some balanced phenos carry a faint floral-linalool sweetness, rounding the edges of the spice. The flavor lingers as a gentle resin note with a cooling aftertaste.

Terp intensity is medium-to-high for a CBD cultivar, often measuring 1.2–2.2% total terpene content by weight in dialed-in indoor grows. Sun-grown expressions can push a brighter citrus-herbal register, though terp totals may tighten to the 0.8–1.6% range depending on climate and cure. Proper curing at 60% relative humidity consistently retains top notes and preserves the piney backbone.

Cannabinoid Architecture and Typical Lab Results

Parent-line data help set expectations. AC/DC commonly tests at ~14–20% CBD with <1% THC, Canna-Tsu at ~7–15% CBD with low THC, Suzy Q around ~10–20% CBD with low THC, and NL5 at ~18–22% THC with minimal CBD. The combined cross therefore spans a wide ratio potential from CBD-dominant to balanced, with careful selection skewing toward CBD.

In practice, growers report three recurring chemotype bands. CBD-dominant phenotypes often test at 9–16% CBD with 0.3–2.0% THC, yielding ratios in the 8:1 to 25:1 range, median around 12:1. Balanced phenotypes can land between 6–12% CBD and 6–12% THC, clustering near 1:1 to 2:1 ratios.

THC-leaning outliers may show 14–20% THC with sub-2% CBD, reminiscent of NL5 influence and often selected out for medical markets. Selection pressure and filial stabilization reduce these outliers over successive seed generations. Clone-only keeper cuts, once confirmed, tend to reproduce ratios within ±10–15% across harvests under similar environments.

Minor cannabinoids contribute subtly to the experience. Labs on similar lineages frequently detect CBG at 0.2–0.8% and CBC at 0.1–0.4%, with trace THCV or CBDV occasionally appearing below 0.2%. Total cannabinoids on dialed-in runs typically reach 12–22%, depending on phenotype and cultivation intensity.

Terpene Profile and Volatile Chemistry

This cultivar’s terpene spectrum generally orbits around myrcene, beta-caryophyllene, alpha-pinene, and limonene, supported by humulene and linalool. Typical indoor totals range from 1.2% to 2.2% by dry weight, with top phenos approaching 2.5% under high-PPFD, cool-cure regimens. Sun-grown flower often displays broader monoterpene diversity, though totals may be slightly lower.

Representative distributions for standout CBD-dominant phenotypes include myrcene at 0.4–0.8%, beta-caryophyllene at 0.2–0.6%, alpha-pinene at 0.2–0.5%, and limonene at 0.1–0.4%. Humulene commonly lands at 0.05–0.2% and linalool at 0.03–0.15%. Trace ocimene or terpinolene can appear, especially in more sativa-leaning expressions.

Functionally, pinene and limonene support mental clarity and perceived energy, aligning with the cultivar’s daytime suitability. Myrcene and linalool add body relaxation and gentle calm without the heaviness associated with sedative indica chemotypes. Beta-caryophyllene’s CB2 receptor affinity contributes to the anti-inflammatory potential often reported anecdotally.

Storage and handling significantly influence terpene retention. Research indicates terpene losses exceeding 30% can occur with high-heat drying or prolonged jar burping. Following the 60/60 cure guideline—60°F/15.5°C and 60% RH—best preserves volatile fractions, helping maintain both flavor and effects consistency.

Experiential Effects and Use Cases

Most users describe a calm, clear-headed onset within minutes when inhaled, often without the disorientation associated with THC-rich strains. The mood lift is gentle but discernible, frequently noted as a reduction in background anxiety and muscular tension. Functional focus tends to remain intact, making it viable for daytime tasks.

Balanced phenotypes with higher THC fractions can add a soft, euphoric glow and enhanced sensory appreciation. Even so, the CBD buffer usually attenuates the intensity and short-term memory disruption that some users experience with THC. Reports of couchlock are uncommon unless higher doses are used or nighttime phenotypes lean more myrcene-heavy.

Inhalation onset is typically 2–5 minutes with peak effects at 15–30 minutes and a 2–3 hour duration. Oral routes can take 45–90 minutes to onset with 4–8 hours of effect, depending on metabolism and fed state. Sublingual tinctures often bridge these profiles with a 15–45 minute onset and 3–5 hour duration.

Common use cases include daytime stress management, focus-oriented creative work, low-grade pain, and social ease without intoxication. Athletes and active users may appreciate the post-activity muscle relaxation without cognitive fog. For sleep, users often layer this cultivar with a CBN-rich preparation or choose a more sedative chemotype if insomnia is primary.

Potential Medical Applications and Evidence

CBD carries a substantial evidence base for seizure reduction in certain epilepsies. In randomized controlled trials, cannabidiol achieved median seizure reductions around 37–42% in Lennox–Gastaut and Dravet syndromes, which led to regulatory approvals of CBD formulations. While smoked or vaporized flower is not equivalent to standardized pharmaceuticals, CBD-dominant cannabis may offer adjunctive benefit for select patients under medical guidance.

Anxiety is another target area, with studies showing acute CBD doses of around 300 mg reducing anxiety in simulated public speaking tasks. While the dose delivered by flower will be lower, the presence of linalool, limonene, and beta-caryophyllene may contribute synergistically to anxiolytic effects. Patient reports frequently cite reduced rumination and smoother mood trajectories without sedation during the day.

For pain and inflammation, meta-analyses of cannabinoids suggest modest benefits, with stronger data for neuropathic pain. Beta-caryophyllene’s CB2 agonism and CBD’s anti-inflammatory signaling through TRPV1 and adenosine pathways may underpin the relief some users experience. Inflammatory conditions such as arthritis often respond to CBD-rich regimens in patient surveys, though high-quality trials remain limited.

Other areas of interest include spasticity, PTSD-related hyperarousal, and migraine frequency. CBD’s safety profile is generally favorable, with common side effects including fatigue, dry mouth, and GI upset at higher doses. Drug–drug interactions, particularly via CYP450 enzymes, warrant medical oversight for patients on polypharmacy, including warfarin, clobazam, and certain antidepressants.

Cultivation Guide: Environment, Training, and Nutrition

This cultivar performs well in controlled indoor environments and greenhouses, with outdoor success in dry, temperate climates. Target daytime temperatures of 22–26°C and nighttime at 18–21°C, maintaining a VPD of 0.8–1.2 kPa during flower. Relative humidity should sit around 60–70% in early veg, tapering to 45–55% in late flower to mitigate mildew.

Lighting can range from 600–900 PPFD in veg to 900–1200 PPFD in flower, with a daily light integral target of 35–45 mol/m²/day for flowering plants. CO2 supplementation at 900–1200 ppm can improve biomass and yield by 10–20% if other parameters are optimized. The plant’s internode pattern benefits from even light spread; consider bar-style LEDs for uniform canopy penetration.

Training strategies such as topping at the 4th–5th node, low-stress training, and SCROG produce the best canopy density. Avoid aggressive high-stress techniques after week 2 of flower to prevent hormonal disruptions that may affect resin maturation. Plants respond well to two toppings in early veg, producing 8–12 dominant colas in a 5–10 gallon container.

Nutritionally, this cultivar prefers a moderate feed. In inert media, maintain EC at 1.2–1.6 in veg and 1.6–1.8 in peak flower, with pH 5.8–6.2 for hydro/soilless and 6.2–6.8 for soil. Cal-Mag supplementation is often beneficial under LED lighting, and sulfur availability is important for terpene synthesis; tissue tests can guide fine-tuning.

Irrigation frequency should match root zone oxygenation needs. In coco, fertigate to 10–20% runoff once to twice daily in peak growth; in living soil, water more deeply but less frequently, keeping volumetric water content steady. Aim for canopy airflow of 0.5–1.0 m/s with multidirectional fans and a 15–25% hourly air exchange to reduce disease pressure.

Cultivation Guide: Flowering, Harvest, and Post-Harvest

Flowering time averages 56–70 days indoors, with many CBD-dominant phenotypes finishing around days 60–63. Outdoor harvest aligns with late September to mid-October in the Northern Hemisphere, depending on latitude and phenotype. Balanced chemotypes may take a few days longer as they continue to pack on resin in the final week.

Yield potential is strong for a CBD cultivar. Indoors, expect 400–550 g/m² under 900–1100 PPFD, rising to 600 g/m² in optimized CO2-assisted rooms. Outdoors, well-grown plants in 25–50 gallon containers can return 600–900 g per plant, with exceptional specimens exceeding 1 kg.

Trichome maturity should be monitored with an eye toward CBD peak timing. CBD often peaks slightly earlier than THC; harvesting when trichomes are predominantly cloudy with minimal amber (5–15%) can preserve a higher CBD:THC ratio. Waiting for heavy ambering may shift the ratio toward THC relative to CBD and induce a heavier, sleepier effect profile.

Drying at 60°F/15.5°C and 55–60% RH for 10–14 days preserves terpenes and stabilizes water activity in the 0.55–0.65 Aw range. After stem snaps but before brittleness, trim carefully to protect trichomes. Cure in airtight containers at 58–62% RH, burping lightly in the first 7–10 days, then weekly checks for 2–6 weeks.

Post-harvest testing is recommended to validate targets. Keepers destined for medical markets typically show CBD:THC ratios above 10:1 and consistent totals across successive harvests within ±10–15%. If compliance with <0.3% THC is required, note that few cannabis chemotypes from this cross qualify as hemp; early harvest or specialized selection is necessary and should be confirmed via HPLC.

Phenotype Hunting, Stability, and Compliance

Begin with a sizeable seed run to sample the chemotype diversity inherent in this polyhybrid. A practical approach is to germinate 50–100 seeds, grow them to clone-taking size, and preserve a clone of each prior to flowering. Flower the seed plants, test top colas at week 7–9 via HPLC, and shortlist CBD-dominant candidates for a second verification